Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers (Q40485588)

20 September 2017

title

Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers (English)

1 reference

20 September 2017

Scheid DC

1

1 reference

20 September 2017

Hamm RM

series ordinal

2

1 reference

20 September 2017

Stevens KW

series ordinal

3

1 reference

20 September 2017

publication date

1 October 2000

1 reference

20 September 2017

1 reference

20 September 2017

volume

18

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

355-368

1 reference

Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: an interim analysis

20 September 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200018040-00004

Lifetime cost of human immunodeficiency virus-related health care

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200018040-00004

Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200018040-00004

Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs.

21 January 2018

1 reference

12 December 2020

Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1.

1 reference

12 December 2020

Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. The CDC Cooperative Needlestick Surveillance Group

1 reference

12 December 2020

A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group

1 reference

12 December 2020

Zidovudine toxicity in uninfected healthcare workers

1 reference

12 December 2020

Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview

1 reference

12 December 2020

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

12 December 2020

Postexposure chemoprophylaxis for occupational exposure to human immunodeficiency virus type 1: current status and prospects for the future

1 reference

12 December 2020

Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial

1 reference

12 December 2020

Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population-based cohort

1 reference

12 December 2020

Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach

1 reference

12 December 2020

The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection

1 reference

12 December 2020

Markov models in medical decision making: a practical guide.

1 reference

12 December 2020

Zidovudine prophylaxis after accidental exposure to HIV: the Italian experience. The Italian Study Group on Occupational Risk of HIV Infection

1 reference

12 December 2020

Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs

1 reference

12 December 2020

Cost-effectiveness of prophylactic AZT following needlestick injury in health care workers

1 reference

12 December 2020

Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method.

1 reference

12 December 2020

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

1 reference

12 December 2020

The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.

1 reference

12 December 2020

Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis

1 reference

12 December 2020

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

12 December 2020

Prophylaxis for occupational exposure to HIV.

1 reference

12 December 2020

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

1 reference

12 December 2020

The lifetime cost of treating a person with HIV.

1 reference

12 December 2020

Occupational risk of the acquired immunodeficiency syndrome among health care workers.

1 reference

12 December 2020

Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance

1 reference

12 December 2020

The Markov process in medical prognosis.

1 reference

12 December 2020

Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood--France, United Kingdom, and United States, January 1988-August 1994

1 reference

12 December 2020

Zidovudine for chemoprophylaxis after occupational exposure to HIV-infected blood: an economic evaluation

1 reference

12 December 2020

Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV

1 reference

12 December 2020

Postexposure prophylaxis for human immunodeficiency virus at San Francisco General Hospital

1 reference

12 December 2020

10.2165/00019053-200018040-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

20 September 2017

1031420421

0 references

1 reference